Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab | Zendy

Sophie Restellini | Zendy; CheYung Chao | Zendy; Péter L. Lakatos | Zendy; Achuthan Aruljothy | Zendy; Haya Aziz | Zendy; Omar Kherad | Zendy; Alain Bitton | Zendy; Gary Wild | Zendy; Waqqas Afif | Zendy; Talat Bessissow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab

Author(s) -

Sophie Restellini,

CheYung Chao,

Péter L. Lakatos,

Achuthan Aruljothy,

Haya Aziz,

Omar Kherad,

Alain Bitton,

Gary Wild,

Waqqas Afif,

Talat Bessissow

Publication year - 2018

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izy044

Subject(s) - adalimumab , medicine , therapeutic drug monitoring , drug , crohn's disease , intensive care medicine , pharmacology , tumor necrosis factor alpha , disease

Managing loss of response (LOR) in Crohn's disase (CD) patients remains challenging. Compelling evidence supports therapeutic drug monitoring (TDM) to guide management in patients on infliximab, but data for other biologics are less robust. We aimed to asses if empiric dose escalation led to improved clinical outcome in addition to TDM-guided optimization in CD patients with LOR to adalimumab (ADA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research